No selection of CXCR4-using variants in cell reservoirs of dual-mixed HIV infected patients receiving suppressive maraviroc therapy

No selection of CXCR4-using variants in cell reservoirs of dual-mixed HIV infected patients receiving suppressive maraviroc therapy

Bibliographic Details
Main Authors:	J. Izopet, S. Raymond, F. Nicot, N. Jeanne, P. Delobel
Format:	Article
Language:	English
Published:	Elsevier 2015-12-01
Series:	Journal of Virus Eradication
Online Access:	http://www.sciencedirect.com/science/article/pii/S2055664020313789

Similar Items

Maraviroc (Celsentri) in HIV treatment
by: Viola Sacchi
Published: (2008-01-01)

Lack of effect of Maraviroc intensification on blood and gut reservoir.
by: Tiraboschi, J, et al.
Published: (2016)

Effectiveness and cost of treatment with maraviroc in HIV infection
by: Viola Sacchi, et al.
Published: (2009-01-01)

Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification
by: Jintanat Ananworanich, et al.
Published: (2015-04-01)

Maraviroc: a review of its use in HIV infection and beyond
by: Woollard SM, et al.
Published: (2015-10-01)

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients
by: Gonzalez-Serna A, et al.
Published: (2016-01-01)

Synergistic anti-HIV-1 activity of griffithsin with tenofovir, maraviroc and enfuvirtide
by: Schols Dominique, et al.
Published: (2011-10-01)

Impact of maraviroc on immune restoration in an advanced stage HIV-infected patient
by: Poizot-Martin Isabelle, et al.
Published: (2010-05-01)

Maraviroc – a CCR5 antagonist for the treatment of HIV-1 infection
by: Elna eVan Der Ryst
Published: (2015-06-01)

Development and evaluation of mucoadhesive bigel containing tenofovir and maraviroc for HIV prophylaxis
by: Margaret O. Ilomuanya, et al.
Published: (2020-11-01)

30LB Maraviroc administration is associated to reversion of latent HIV-1 through NFkB in ART suppressed patients
by: N. Madrid-Elena, et al.
Published: (2016-07-01)

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc.
by: Christophe Rodriguez, et al.
Published: (2015-01-01)

Use of maraviroc, the first CCR5 receptor antagonist, in HIV treatment regimens
by: A V Kravchenko
Published: (2013-11-01)

Effect of maraviroc intensification on HIV-1-specific T cell immunity in recently HIV-1-infected individuals.
by: Ai Kawana-Tachikawa, et al.
Published: (2014-01-01)

Economic modeling in HIV for maraviroc in France in treatment experienced patients. Results from the ARAMIS 2011 model
by: Despiegel Nicolas, et al.
Published: (2012-05-01)

Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound
by: María Rosa López-Huertas, et al.
Published: (2020-12-01)

Optimizing management of treatment-na&iuml;ve and treatment-experienced HIV+ patients: the role of maraviroc
by: Eva Poveda, et al.
Published: (2010-03-01)

Parameters Influencing Baseline HIV-1 Genotypic Tropism Testing Related to Clinical Outcome in Patients on Maraviroc.
by: Saleta Sierra, et al.
Published: (2015-01-01)

Durability and Effectiveness of Maraviroc-Containing Regimens in HIV-1-Infected Individuals with Virological Failure in Routine Clinical Practice.
by: Valérie Potard, et al.
Published: (2015-01-01)

The Discovery and Exploratory Development of Maraviroc (UK-427,857): A Novel CCR5 Antagonist for the Treatment of HIV
by: Hitchcock CA
Published: (2005-12-01)

Stochastic model of in-vivo X4 emergence during HIV infection: implications for the CCR5 inhibitor maraviroc.
by: Borislav Savkovic, et al.
Published: (2012-01-01)

CCR5/CXCR4 Dual Antagonism for the Improvement of HIV Infection Therapy
by: Fedora Grande, et al.
Published: (2019-02-01)

Clonal analysis of HIV-1 genotype and function associated with virologic failure in treatment-experienced persons receiving maraviroc: Results from the MOTIVATE phase 3 randomized, placebo-controlled trials.
by: Marilyn Lewis, et al.
Published: (2018-01-01)

Maraviroc Prevents HCC Development by Suppressing Macrophages and the Liver Progenitor Cell Response in a Murine Chronic Liver Disease Model
by: Adam M. Passman, et al.
Published: (2021-09-01)

Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure.
by: Pierre Delobel, et al.
Published: (2011-01-01)

Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients.
by: Nicholas Funderburg, et al.
Published: (2010-10-01)

Levels of soluble endothelial protein C receptor are associated with CD4+ changes in Maraviroc-treated HIV-infected patients.
by: Silvia Nozza, et al.
Published: (2012-01-01)

The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1
by: María Rosa López-Huertas, et al.
Published: (2017-05-01)

Natural scrub typhus antibody suppresses HIV CXCR4(X4) viruses
by: George Watt, et al.
Published: (2013-05-01)

Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial.
by: Barbara Rossetti, et al.
Published: (2017-01-01)

Fármacos recentes usados para o tratamento da infecção pelo HIV-1: enfuvirtida, maraviroc, raltegravir e etravirina
by: M.A. Brito
Published: (2011-05-01)

Maraviroc reactivates HIV with a potency similar to that of other latency reversing drugs without inducing toxicity in CD8 T cells
by: S. Moreno, et al.
Published: (2019-12-01)

Role of maraviroc and/or rapamycin in the liver of IL10 KO mice with frailty syndrome.
by: Laura Pérez-Martínez, et al.
Published: (2024-01-01)

CXCR7 maintains osteosarcoma invasion after CXCR4 suppression in bone marrow microenvironment
by: Yan Han, et al.
Published: (2017-04-01)

Structure and dynamics of the gp120 V3 loop that confers noncompetitive resistance in R5 HIV-1(JR-FL) to maraviroc.
by: Yuzhe Yuan, et al.
Published: (2013-01-01)

In vitro downregulation of matrix metalloproteinase-9 in rat glial cells by CCR5 antagonist maraviroc: therapeutic implication for HIV brain infection.
by: Pasqua Gramegna, et al.
Published: (2011-01-01)

CXCR2 intrinsically drives the maturation and function of neutrophils in mice
by: Pauline Delobel, et al.
Published: (2022-10-01)

Multivariate Chemometric Comparison of Forced Degradation and Electrochemical Oxidation LC–MS Profiles of Maraviroc
by: Michał Wroński, et al.
Published: (2023-01-01)

A drug interaction study investigating the effect of Rifabutin on the pharmacokinetics of Maraviroc in healthy subjects.
by: M Ghannad, et al.
Published: (2019-01-01)

Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model.
by: C Preston Neff, et al.
Published: (2010-12-01)